Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
Nancy U. Lin(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), Sherene Loi(The University of Melbourne), Carey K. Anders(Duke University), Michael P. DiGiovanna(Goethe University Frankfurt), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Amelia Zelnak(Northside Hospital), Philippe L. Bédard(Princess Margaret Cancer Centre), Thomas Bachelot(Centre Léon Bérard), Lisa A. Carey(University of North Carolina at Chapel Hill), A. Jo Chien(University of California, San Francisco), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Andrew Wardley(UK Research and Innovation), Sara A. Hurvitz(University of Washington), Vandana G. Abramson(Vanderbilt University), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Grace An, Virginia F. Borges(University of Colorado Anschutz Medical Campus), Volkmar Müller(Universität Hamburg), Suzanne McGoldrick(Seagen (United States))
Cited by 12
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k